Telehealth and Telecare News since 2005 ...

Hims & Hers expands to Ireland, France, and Germany, and adds to UK. Announced yesterday, the ambitious strategic acquisition of Zava, a similar online direct to consumer provider of telemedicine ...

Anne Wojcicki still wants her 23andMe. This time, she is requesting that the auction be reopened for more bids–hers, along with a new backer. The unnamed “Fortune 500 company with a current market ...

Your Editor recommends grabbing lunch or a cuppa for these lengthy reads/views: Flawed Federal Programs Maroon Rural Americans in Telehealth Blackouts. This is mostly about the billions spent in ‘last ...

Midi Health broadens mid-life women’s health into longevity–covered by some insurance. Midi Health, which targets women in their middle years (a limiting definition, as this Editor will explain), is ...

Another review/meta-analysis confirms that GLP-1 weight off doesn’t stay off. A University of Oxford systemic review and meta-analysis of 130 full texts, distilled to 11 studies with 6,370 ...

Breaking up is hard to do. But should be done if UHG wants to survive and thrive. Our proposition: UnitedHealth Group has become a victim of its own giantism, conflicts, and focus on financials–and ...

The Masimo website goes offline–coinciding with their investor meeting. When this Editor posted an article on former Masimo CEO Joseph Kiani’s “beneficial ownership” SEC filing (Schedule G/A, for ...

Medical device company Masimo may not be able to rid itself entirely of its meddlesome former CEO, Joe Kiani. In fact, if a court awards him the shares exercised under his various employment ...

Short takes: Veradigm’s interim CEO departing, Blue Shield CA breached 4.8M members’ PHI to Google, advice on expanded M&A premarket notification rules (You can’t blame that CEO for ankling! And Blue ...

Starting with international health tech developments… South Australia Health has rolled out Altera Digital Health’s Sunrise Electronic Medical Record (EMR) and Patient Administration System (PAS). The ...

Transcarent closes Accolade buy, changes its game. Transcarent’s $621 million acquisition of Accolade was wrapped up in record time (two months from announcement). This takes the Nasdaq-listed ...